Ocular Therapeutix, Inc. (NASDAQ:OCUL) has made a 49.22% comeback from a 12-month low price of $3.84. It was seen -13.96% lower, changing the price to $5.73, when the closing bell rang on 12/03/2018. At recent session, the prices were hovering between $5.695 and $6.42. This company shares are 124.43% off its target price of $12.86 and the current market capitalization stands at $223.57M. The recent change has given its price a -2.12% deficit over SMA 50 and -30.77% deficit over its 52-week high. The stock witnessed 11.26% gains, -15.11% declines and -16.47% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found OCUL’s volatility during a week at 10.48% and during a month it has been found around 7.94%.Ocular Therapeutix, Inc. (OCUL) Top Holders
Institutional investors currently hold around $145 million or 53.2% in OCUL stock. Look at its top three institutional owners. Summer Road Llc owns $20.16 million in Ocular Therapeutix, Inc., which represents roughly 9.02% of the company’s market cap and approximately 13.91% of the institutional ownership. Similar statistics are true for the second largest owner, Jennison Associates Llc, which owns 2,335,989 shares of the stock are valued at $15.56 million. The third largest holder is Fmr Llc, which currently holds $15.32 million worth of this stock and that ownership represents nearly 6.85% of its market capitalization.Ocular Therapeutix, Inc. 13F Filings
At the end of September reporting period, 37 institutional holders increased their position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by some 1,903,854 shares, 25 decreased positions by 2,057,057 and 19 held positions by 17,746,138. That puts total institutional holdings at 21,707,049 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 886,887 shares while 9 institutional investors sold out their entire positions totaling 101,505 shares.Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Trades
Multiple company employees have indulged in significant insider trading. Ocular Therapeutix, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO Mattessich Antony C. has acquired 20,000 shares of Ocular Therapeutix, Inc. (OCUL) in trading session dated Aug. 20, 2018. These shares are worth $119,000 and were traded at $5.95 each. The SEC filing shows that Notman Donald performed a purchase of 12,500 shares. The CFO added these shares by way of transaction on Aug. 14, 2018. The company’s shares were assimilated at $6.29 per share worth to an investment of some $78,625 on account of Notman Donald.
President and CEO, Mattessich Antony C., purchased 16,900 common shares of Ocular Therapeutix, Inc. (OCUL) in the open market. In a transaction dated Aug. 10, 2018, the shares were bought at an average price of $6.23, giving away a sum of $105,287. After this purchase, 37,900 common shares of OCUL are directly owned by the insider, with total stake valued at $217,167.
In the transaction dated Dec. 12, 2017, the great number of shares acquired came courtesy the President and C.E.O.; Mattessich Antony C. added a total of 21,000 shares at an average price of $4.29, amounting to approximately $90,090. The insider now directly owns 21,000 shares worth $120,330.Ocular Therapeutix, Inc. (OCUL) Analyst Guide
Several analysts have released their opinion on Ocular Therapeutix, Inc. (NASDAQ:OCUL), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.71 average brokerage recommendation.